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Scomplex and "real-world" disease is limited. We report the early experience with ABS
from two Australian centres.
Methods: Between Aug 2010-Jun 2013, 95 lesions in 68 pts were treated with ABS
(64% male, mean age 63 yrs). Diabetes was present in 22% and PCI indication was
ACS in 32% pts. Lesion location was 46% LAD, 41.5% RCA, 10% RCA and 2.5%
SVG. Lesion complexity was 42% B2 or C, 19% moderate/severe calciﬁcation, 4%
CTO, 27% long lesions and 7% bifurcations. Pre-dilatation was used in 100% pts
(rotablator/scoring balloon in 4%). In total, 107 scaffolds were implanted - average
1.6/pt (range 1-5) with average scaffold length/pt 39mm. Scaffold overlap was per-
formed in 31% pts. Multivessel ABS implantation was performed in 8.8% pts. Post-
dilatation was performed in 100% cases. Registry data was collected prospectively in
hospital, day 30, 1 and 2 years post-PCI. To date, 87% of pts have reached 30 days,
34% 12 months and 4% 24 months post-ABS implantation.
Results: Procedural success was 100% and device success 99% (failure to deliver
ABS in 1 pt). A "bail-out" DES was required in 2 (3%) of cases for scaffold edge
dissection. An in-hospital non-Q MI occurred in 1 (1.5%) pt due to athero-thrombotic
distal embolism. There were no other in-hospital clinical events (target vessel revas-
cularization, Q wave MI, scaffold thrombosis or any death). There have been no late
cases of MI (Non-Q or Q wave), target vessel revascularization, scaffold thrombosis or
cardiac death. There was 1 (1.5%) non-cardiac death at 21 months post-ABS
implantation due to renal failure. Overall MACE in late follow-up occurred in 2
(2.9%) pts.
Conclusions: This early Australian experience has demonstrated very high immediate
ABS success in the treatment of complex coronary disease. Additionally, ABS therapy
following rigorous lesion preparation and strict implantation technique is highly safe
and efﬁcacious both in-hospital and in follow-up in "real-world" disease (including
long lesions, CTOs, calciﬁcation, bifurcations and muti-vessel disease).TCT-426
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Background: The experience of the BVS in real world patients with expanded
indications and lesion characterization is limited. We report our experience of the use
of BVS in real world all comers patients from the "Real Absorb Registry".
Methods: Our "Real ABSORB registry" is a single centre registry of all BVS
implanted in real life patients since its approval for unrestricted clinical use in
December 2012 onwards.
Results: Out of 135 patients with 165 lesions were treated with 217 BVS.111 patients
with 189 BVS were outside the Absorb extend criteria. The lesion characteristics are
as follows 40%(54/135) had calciﬁed lesion (CL), 8.8%(12/135) tortuous lesions with
>2 45/>90 angulation.37% (50/135) had Bifurcation lesions (BL),28.8%(39/135)
had long lesion ( one 28 mm Absorb), 20.7%(28/135) had small vessels (<2.5 mm),
9.6%(13/135) had chronic total occlusion, 11.8%(16/135) had ostial involvement and
8.1%(11/135) had ISR. In CL, 11.1%(15/135) required Rotablation and 2.2%(3/135)
had cutting balloon for bed preparation. 11.8%(16/135) required buddy wire for
device delivery. 2.9%(4/135)BVS failed to deliver due to calciﬁed tortuosity and
required Guideliner, catheter. In BL 14%(7/50) had planned 2 stent strategy and
86%(43/50) had provisional single stent strategy.6.9%(3/43)had SB stenting with TAP
technique due to threatened closure. OCT/IVUS done in 17.7%(24/135) and helped to
optimize the result in only 2 patients. All BVS had high pressure dilatation >20 atm
within the recommended limitations of BVS expansion All BVS were deployed
successfully. There is no acute/sub acute thrombosis. 130/135 patients had clinical
follow up and 1(0.7%) patient had sudden death at 50 days of follow up(median 143
days,range 17-163).
Conclusions: Our early experience from the Real Absorb Registry of all the use of
BVS in real world patients suggest high success and low complication rates provided
there is meticulous attention to delivery and implantation techniques. While regular
use of imaging tools may help especially in complex patients, We believe that routine
and regular use of extensive high pressure implantation to be more valuable in opti-
mizing results and avoiding scaffold thrombosis in all real world patients.B132 JACC Vol 62/18/Suppl B j October 27–NovembTCT-427
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Background: Recently, bioresorbable scaffolds (BRS) have been developed as a way
to provide transient vessel scaffold while the post PCI healing process takes place,
going away just after. Among the various BRS in clinical test, the most advanced
program is the ABSORB, which combines a PLLA backbone, coated with a bio-
resorbable polymer containing the antiproliferative drug, everolimus. Because this
BRS is made of polymer, concerns about in human acute recoil have been raised. We
sought to assess the acute recoil of two different metallic DES in comparison to
ABSORB in the treatment of non-complex coronary lesions
Methods: For this study we included 50 patients with de novo lesion in native
coronary arteries of 2.5-3.5mm in diameters and lesion length up to 23mm. Twenty-
ﬁve patients were treated with BRS and compared to 25 patients treated with either
everolimus-eluting cobalt chromium stent (EES, n¼12) or biolimus-eluting stainless
steel stent (BES, n¼13) at a random allocation. Acute absolute recoil was deﬁned as
the difference between mean diameter of the last inﬂated balloon at the highest
pressure (X) and mean lumen diameter of the stent immediately after the last balloon
deﬂation (Y). Acute percent recoil was deﬁned as (X – Y)/X and expressed as
percentage
Results: The 3 cohorts did not differ regarding the basic clinical and angiographic
characteristics. Mean lesion length (11.74  3.91mm in the BRS vs. 10.12 
3.21mm in EES vs. 12.93  5.7mm in the BES cohort, p¼0.7) and RVD (2.62 
0.44mm in the BRS vs. 2.74  0.34mm in the EES vs. 2.59  0.42mm in the BES
group, p¼0.4) were also comparable as well as the rate of post dilatation and balloon
to artery ratio. Notably, acute absolute recoil (0.21  0.13mm with BRS vs. 0.15 
0.08mm with EES and 0.14  0.08mm with BES, p¼0.4) and acute percent
recoil (7.0  4.64% with BRS vs. 4.97  2.22% with EES and 5.66  4.10% with
BES, p¼0.2) did not signiﬁcantly differ from different metal alloys and polymeric
scaffolds
Conclusions: In this small, non-complex cohort, the use of a polymeric scaffold did
not result in higher acute recoil as compared to the two most used metallic alloys. This
ﬁnding should be investigated in more complex scenariosTCT-428
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Background: Vascular restoration therapy using bioresorbable vascular scaffolds
(BVS) is a novel approach for treating coronary disease. However, BVS penetration
rate in the treatment of de-novo coronary stenosis in the real life setting is unknown.
Methods: One hundred BVS were available to be used by 6 trained operators between
November 2012 and March 2013 in a high-volume center. Therefore, consecutive
patients treated by the same operators with drug-eluted stents (DES) or BVS were
prospectively analyzed.
Results: Two hundred and forty-ﬁve consecutive DES/scaffolds implantation to treat
144 patients were performed. Thirty-six BVS (15%) were only used in 24 patients
(17%) as compared to 209 DES (85%) used to treat 120 patients (83%). Patients
treated with BVS were younger (6011 vs. 6512 years; p<0.012), had less diabetes
(21% vs. 53%; p<0.001), less type B2/C lesions (28% vs. 60%; p<0.001) and
necessitate less scaffolds (1.50.7 vs. 1.70.9; p¼0.032) as compared to the DES
patients respectively. The reason of non-BVS implantation was documented at the end
of each case and was as follow: unavailable BVS length i.e. longer than 28mm and
lesion could be covered by one DES (23%); bifurcating lesions involving a side
branch of 2mm diameter or more (17%,); unavailable BVS diameter i.e. superior to
3.5mm (17%); severely calciﬁed lesions (17%); chronic total occlusion lesions (11%);
intrastent restenosis (7%); ST-elevation myocardial infarction with thrombus (6%);
others such as venous graft or multiple previous stenting (2%).
Conclusions: The main direct reason for the lack of BVS take-up is the lesion
complexity. However, indirect unmeasured reasons such as cost, operator experience
or lack of evidence on long-term follow-up can also interfere with the treating
physician decision. Randomised studies showing the beneﬁcial long-term follow-up of
BVS to treat more complex lesions are warranted.er 1, 2013 j TCT Abstracts/POSTER/Bioresorbable Vascular Scaffolds
